Evidence map›Paper›PMID 38448388›Full record

ArticleZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences2023

A case of hyperparathyroidism secondary to tumor-induced osteomalacia.

Youbo Yang, Ping Jin, Shuting Zhang, Ke Chen, Honghui He, Zhaohui Mo, Jingjing Yuan

Open access · greenAbstract readCase Reports
In one paragraph

Article in Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Youbo YangDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013. yangyoubo@126.com.
Ping JinDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013.
Shuting ZhangDepartment of Clinical Laboratory, Third Xiangya Hospital, Central South University, Changsha 410013, China.
Ke ChenDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013.
Honghui HeDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013.
Zhaohui MoDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013.
Jingjing YuanDepartment of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013. 806573918@qq.com.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome in which tumor-induced osteochondrosis is a metabolic bone disease caused by increased renal excretion of phosphorus due to excessive secretion of fibroblast growth factor 23 (FGF23) by tumor tissue. We report here a rare case of TIO in which the tumor was found in the hyoid body and the patient had tertiary hyperparathyroidism. The patient's symptoms did not improve after removal of the tumor from the hyoid body, and the patient's hypophosphatemia was gradually improved after subsequent removal of the left parathyroid gland. TIO derived from the tongue tumor is very rare, and also subsequent tertiary hyperparathyroidism is even rarer. This report helps to improve the understanding of TIO and provides reference in the diagnosis and treatment of TIO.

Indexed as

HyperparathyroidismOsteomalaciaParaneoplastic SyndromesHumansParathyroid Glandsfibroblast growth factor 23hyperparathyroidismphosphatiduric mesenchymal tumortumor-induced osteomalacia

Identifiers

PMID38448388
PMCPMC10930739
OpenAlexW4394758292

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.